Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rocket Pharmaceuticals Inc
(NQ:
RCKT
)
22.66
+1.14 (+5.30%)
Streaming Delayed Price
Updated: 2:31 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rocket Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
October 10, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
October 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Rocket Pharmaceuticals
September 30, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Rocket Pharmaceuticals
July 26, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
4 Analysts Have This to Say About Rocket Pharmaceuticals
July 06, 2022
Within the last quarter, Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings:
Via
Benzinga
Citigroup To $47? Plus This Analysts Predict $95 For Papa John's
October 03, 2022
Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading.
Via
Benzinga
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306%
October 03, 2022
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...
Via
Benzinga
Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor
September 30, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023.
Via
Benzinga
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 30, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
September 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, STOR, RCKT, RCOR
September 22, 2022
Via
ACCESSWIRE
Why Is Renovacor (RCOR) Stock Up 18% Today?
September 20, 2022
Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal.
Via
InvestorPlace
Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases
September 20, 2022
Via
Benzinga
RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders
September 20, 2022
From
Halper Sadeh LLC
Via
Business Wire
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
September 20, 2022
From
Rocket Pharmaceuticals, Inc. and Renovacor, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 16, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
August 11, 2022
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.
Via
Investor's Business Daily
Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
August 09, 2022
Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up...
Via
Benzinga
Rocket Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
July 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Why Jim Cramer Says This Stock Is 'Definitely A Buy'
July 20, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is with Tellurian Inc. (NYSE: TELL).
Via
Benzinga
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
July 08, 2022
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
July 08, 2022
Via
Benzinga
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.